trending Market Intelligence /marketintelligence/en/news-insights/trending/eOxwheKvKzL-7dsUkLAIQg2 content esgSubNav
In This List

Pluristem to advance blood transplant study

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Pluristem to advance blood transplant study

Pluristem Therapeutics Inc. is collaborating with the New York Blood Center to advance studies on its PLX-R18 therapy for umbilical cord blood transplantation.

The study will be funded by a conditional award of $900,000 from the Israel-U.S. Binational Industrial Research and Development Foundation with Pluristem providing the PLX-R18 cells and the NYBC conducting and supporting the studies.